In an in vivo study, Huang et al. administered HF at doses of 20 or 40 mg/kg to MDA-MB-231 breast tumor-bearing mice over 21 days, resulting in a significant reduction in tumor weight alongside a marked decrease in Ki-67-positive proliferating cells, thus confirming HF’s antitumor efficacy and its impact on cell proliferation within the TME. The gene discussed is MKI67; the disease is neoplasm.